Parallax Volatility Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.16M | Sell |
8,500
-428,800
| -98% | -$53.5M | ﹤0.01% | 895 |
|
|
2025
Q4 | $53.3M | Buy |
437,300
+365,500
| +509% | +$41.9M | 0.11% | 150 |
|
|
2025
Q3 | $7.19M | Buy |
71,800
+64,200
| +845% | +$5.78M | 0.01% | 579 |
|
|
2025
Q2 | $630K | Sell |
7,600
-12,600
| -62% | -$1.01M | ﹤0.01% | 1147 |
|
|
2025
Q1 | $1.64M | Sell |
20,200
-205,100
| -91% | -$18.3M | ﹤0.01% | 921 |
|
|
2024
Q4 | $20.3M | Sell |
225,300
-414,000
| -65% | -$40.1M | 0.04% | 342 |
|
|
2024
Q3 | $63.2M | Sell |
639,300
-66,400
| -9% | -$6.52M | 0.12% | 139 |
|
|
2024
Q2 | $65.4M | Buy |
705,700
+99,000
| +16% | +$8.88M | 0.14% | 116 |
|
|
2024
Q1 | $57.6M | Buy |
606,700
+431,000
| +245% | +$40M | 0.13% | 143 |
|
|
2023
Q4 | $15.7M | Sell |
175,700
-14,500
| -8% | -$1.08M | 0.03% | 457 |
|
|
2023
Q3 | $13.9M | Buy |
190,200
+89,600
| +89% | +$7.16M | 0.03% | 436 |
|
|
2023
Q2 | $8.37M | Sell |
100,600
-112,100
| -53% | -$9.37M | 0.02% | 594 |
|
|
2023
Q1 | $16.2M | Sell |
212,700
-212,100
| -50% | -$17.6M | 0.03% | 429 |
|
|
2022
Q4 | $35.3M | Buy |
424,800
+69,100
| +19% | +$5.59M | 0.05% | 362 |
|
|
2022
Q3 | $28.2M | Sell |
355,700
-1,283,000
| -78% | -$108M | 0.04% | 427 |
|
|
2022
Q2 | $122M | Sell |
1,638,700
-1,487,600
| -48% | -$112M | 0.12% | 123 |
|
|
2022
Q1 | $281M | Buy |
3,126,300
+1,971,400
| +171% | +$182M | 0.15% | 37 |
|
|
2021
Q4 | $129M | Buy |
1,154,900
+312,100
| +37% | +$37.6M | 0.15% | 88 |
|
|
2021
Q3 | $106M | Buy |
842,800
+459,000
| +120% | +$59.1M | 0.1% | 145 |
|
|
2021
Q2 | $52M | Buy |
383,800
+313,800
| +448% | +$41.3M | 0.07% | 188 |
|
|
2021
Q1 | $9.5M | Sell |
70,000
-179,400
| -72% | -$26.9M | 0.02% | 394 |
|
|
2020
Q4 | $35.1M | Sell |
249,400
-130,800
| -34% | -$16.8M | 0.04% | 386 |
|
|
2020
Q3 | $42.4M | Buy |
380,200
+99,400
| +35% | +$11.1M | 0.03% | 453 |
|
|
2020
Q2 | $31.4M | Buy |
280,800
+115,800
| +70% | +$11.4M | 0.04% | 381 |
|
|
2020
Q1 | $12.8M | Buy |
165,000
+142,100
| +621% | +$12.6M | 0.02% | 523 |
|
|
2019
Q4 | $2.18M | Sell |
22,900
-39,300
| -63% | -$3.4M | ﹤0.01% | 1226 |
|
|
2019
Q3 | $4.75M | Sell |
62,200
-21,100
| -25% | -$1.75M | 0.01% | 829 |
|
|
2019
Q2 | $7.31M | Sell |
83,300
-211,300
| -72% | -$18M | 0.01% | 602 |
|
|
2019
Q1 | $26.7M | Buy |
294,600
+98,000
| +50% | +$8.34M | 0.03% | 264 |
|
|
2018
Q4 | $14.1M | Sell |
196,600
-252,000
| -56% | -$20.3M | 0.02% | 427 |
|
|
2018
Q3 | $43M | Sell |
448,600
-1,108,400
| -71% | -$107M | 0.05% | 161 |
|
|
2018
Q2 | $148M | Buy |
1,557,000
+1,307,000
| +523% | +$120M | 0.21% | 47 |
|
|
2018
Q1 | $21.9M | Buy |
250,000
+225,000
| +900% | +$20.5M | 0.03% | 238 |
|
|
2017
Q4 | $2.12M | Sell |
25,000
-4,200
| -14% | -$352K | ﹤0.01% | 898 |
|
|
2017
Q3 | $2.53M | Sell |
29,200
-200,000
| -87% | -$16M | ﹤0.01% | 779 |
|
|
2017
Q2 | $17.7M | Sell |
229,200
-80,000
| -26% | -$5.67M | 0.03% | 277 |
|
|
2017
Q1 | $21.4M | Buy |
309,200
+283,400
| +1,098% | +$19M | 0.04% | 232 |
|
|
2016
Q4 | $1.53M | Sell |
25,800
-1,030,000
| -98% | -$63.6M | ﹤0.01% | 1070 |
|
|
2016
Q3 | $70M | Buy |
1,055,800
+605,100
| +134% | +$37.4M | 0.13% | 110 |
|
|
2016
Q2 | $24.4M | Buy |
450,700
+28,000
| +7% | +$1.53M | 0.05% | 246 |
|
|
2016
Q1 | $21.8M | Buy |
422,700
+322,700
| +323% | +$16.8M | 0.05% | 233 |
|
|
2015
Q4 | $7.02M | Sell |
100,000
-98,000
| -49% | -$6.68M | 0.01% | 562 |
|
|
2015
Q3 | $12.3M | Sell |
198,000
-198,000
| -50% | -$15.6M | 0.03% | 368 |
|
|
2015
Q2 | $33.3M | Buy |
396,000
+395,700
| +131,900% | +$30.8M | 0.07% | 185 |
|
|
2015
Q1 | $23K | Buy |
+300
| New | +$21K | ﹤0.01% | 3522 |
|
|
2014
Q3 | – | Sell |
-12,000
| Closed | -$615K | – | 4554 |
|
|
2014
Q2 | $615K | Buy |
12,000
+11,100
| +1,233% | +$500K | ﹤0.01% | 1285 |
|
|
2014
Q1 | $42K | Buy |
+900
| New | +$46.1K | ﹤0.01% | 2407 |
|
|
2013
Q4 | – | Sell |
-2,400
| Closed | -$104K | – | 3623 |
|
|
2013
Q3 | $104K | Buy |
+2,400
| New | +$97.2K | ﹤0.01% | 1423 |
|
Other funds holding XBI
Parallax Volatility Advisers's XBI Position: Q1 2026 in Review
Parallax Volatility Advisers increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1,363,300% in Q1 2026, buying an estimated $1.7M and bringing the position to 13,634 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #803.
Parallax Volatility Advisers first reported a position in XBI in Q2 2014 and has held it in 48 quarters since. The position peaked at $44.9M in Q2 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Parallax Volatility Advisers held 13,634 shares of State Street SPDR S&P Biotech ETF worth $1.86M as of Q1 2026.
- Parallax Volatility Advisers bought 13,633 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.7M.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q1 2026, its #803 holding.
- Parallax Volatility Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and has held it in 48 quarters since.
- Parallax Volatility Advisers's State Street SPDR S&P Biotech ETF position peaked at $44.9M in Q2 2022.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.